Traws Pharma (TRAW) reported a third-quarter 2026 net loss of $3.5 million, or $0.18 per basic and diluted common share, compared with a $4.0 million loss in the prior-year quarter. The company reported no revenue for the quarter ended September 30, 2026.
Traws said its final Phase 2a ratutrelvir study supported further evaluation in COVID-19 patients ineligible for PAXLOVID, while its tivoxavir marboxil tablet bridging study and toxicology retesting supported a planned fourth-quarter regulatory resubmission.
- Cash and cash equivalents were $2.3 million at September 30, 2026, versus $3.8 million at December 31, 2025.
- Research and development expense was $1.8 million, down from $2.3 million a year earlier.
- General and administrative expense was $1.8 million, compared with $1.7 million in the prior-year quarter.
- The company entered a $50 million common-stock purchase agreement with Roth Principal Investments on October 23, 2026; no shares had been sold under the agreement.
- Traws had 15,368,277 common shares outstanding as of November 13, 2026.
$TRAW Hedge Fund Activity
We have seen 12 institutional investors add shares of $TRAW stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SQUADRON CAPITAL MANAGEMENT LLC removed 511,714 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $431,528
- DAUNTLESS INVESTMENT GROUP, LLC removed 336,424 shares (-80.7%) from their portfolio in Q2 2026, for an estimated $283,706
- IKARIAN CAPITAL, LLC removed 200,000 shares (-29.5%) from their portfolio in Q2 2026, for an estimated $168,660
- JANE STREET GROUP, LLC removed 196,921 shares (-91.2%) from their portfolio in Q3 2026, for an estimated $116,931
- VANGUARD CAPITAL MANAGEMENT LLC removed 177,200 shares (-53.7%) from their portfolio in Q3 2026, for an estimated $105,221
- ALYESKA INVESTMENT GROUP, L.P. added 164,376 shares (+inf%) to their portfolio in Q2 2026, for an estimated $138,618
- PALUMBO WEALTH MANAGEMENT LLC removed 61,175 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $51,588
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.